Gene therapy safety study for Stargardt disease in teens
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new gene therapy called HG005 for Stargardt disease in young people aged 6 to 17. It aims to see if the treatment is safe and tolerable, and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have been diagnosed with Stargardt disease.
- You have a specific gene change (ABCA4) on both sides of your DNA.
- Both of your eyes have damage in the central vision area (macula) from Stargardt disease.
- You agree to use contraception during the study.
- You can attend all study visits and follow the rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
Hear when a new Stargardt Disease Type 1 (STGD1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.